Levosimendan’s ability on veno-arterial extracorporeal membrane oxygenation weaning: Evidence says yes!

Marabotti, Alberto; Bertini, Pietro; Paternoster, Gianluca; Landoni, Giovanni; Guarracino, Fabio

doi:10.1177/03913988221145502

Cited by 1 publication

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While waiting for the two ongoing randomized trials, LEVOECMO and Weanlevo (NCT04158674), the best available scientific evidence on the beneficial effects of levosimendan in facilitating the weaning from VA-ECMO comes from Marabotti et al They confirm a higher rate of VA-ECMO weaning and a reduced risk of mortality using levosimendan [ 30 ].…”

Section: The Role Of Left Ventricular Unloading Systems During Eclsmentioning

confidence: 99%

Extracorporeal Life Support in Myocardial Infarction: New Highlights

Piccone,

Schiavoni,

Mattei

et al. 2024

Medicina

View full text Add to dashboard Cite

Background and Objectives: Cardiogenic shock (CS) is a potentially severe complication following acute myocardial infarction (AMI). The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) in these patients has risen significantly over the past two decades, especially when conventional treatments fail. Our aim is to provide an overview of the role of VA-ECMO in CS complicating AMI, with the most recent literature highlights. Materials and Methods: We have reviewed the current VA-ECMO practices with a particular focus on CS complicating AMI. The largest studies reporting the most significant results, i.e., overall clinical outcomes and management of the weaning process, were identified in the PubMed database from 2019 to 2024. Results: The literature about the use of VA-ECMO in CS complicating AMI primarily has consisted of observational studies until 2019, generating the need for randomized controlled trials. The EURO-SHOCK trial showed a lower 30-day all-cause mortality rate in patients receiving VA-ECMO compared to those receiving standard therapy. The ECMO-CS trial compared immediate VA-ECMO implementation with early conservative therapy, with a similar mortality rate between the two groups. The ECLS-SHOCK trial, the largest randomized controlled trial in this field, found no significant difference in mortality at 30 days between the ECMO group and the control group. Recent studies suggest the potential benefits of combining left ventricular unloading devices with VA-ECMO, but they also highlight the increased complication rate, such as bleeding and vascular issues. The routine use of VA-ECMO in AMI complicated by CS cannot be universally supported due to limited evidence and associated risks. Ongoing trials like the Danger Shock, Anchor, and Recover IV trials aim to provide further insights into the management of AMI complicated by CS. Conclusions: Standardizing the timing and indications for initiating mechanical circulatory support (MCS) is crucial and should guide future trials. Multidisciplinary approaches tailored to individual patient needs are essential to minimize complications from unnecessary MCS device initiation.

show abstract

Section: The Role Of Left Ventricular Unloading Systems During Eclsmentioning

confidence: 99%